Efficacy, safety and pharmacokinetic results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Willebrand Factor/factor VIII concentrate (Voncento ®) in subjects with hemophilia A (the SWIFT-HA study)